This response involves increased expression of genes with tumor-suppressive properties (e.g., Txnip, Zbtb16, Timp3 and Cdkn1a), decreased expression of genes associated with cellular transformation and proliferation (e.g., Tmsb10, Sparc and Hspb1), as well as the induction of genes with anti-inflammatory (e.g., Nfkbia, Timp3) or anti-oxidative effects (e.g., Mt1, Mt2). The gene discussed is SPARC; the disease is neoplasm.